Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly
understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate …

Despite the initial successes of immunotherapy, there is an urgent clinical need for
molecular assays that identify patients more likely to respond. Here, we report that …

In the past several years, immunotherapy has emerged as a viable treatment option for
patients with advanced non‐small cell lung cancer (NSCLC) without actionable driver …

Introduction The combination of programmed cell death protein-1 or programmed death-
ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment …

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

Tuberous sclerosis complex subunit 1 (TSC1) and 2 (TSC2) are frequently mutated in non–
small cell lung cancer (NSCLC), however, their effects on antitumor immunity remained …

Introduction The understanding of immune checkpoint molecules' co-expression in non–
small cell lung carcinoma (NCLC) is important to potentially design combinatorial …

Immune checkpoint blockade against programmed cell death 1 (PD-1) and its ligand PD-L1
often induces durable tumor responses in various cancers, including non–small cell lung …

Despite their key regulatory role and therapeutic potency, the molecular signatures of
interactions between T cells and antigen-presenting myeloid cells within the tumor …

Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-
1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to …